Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WU-WEI BAO-GAN WAN
- Development stage
- Phase 1
- Lead developer
- Qingdao Hospital of Chinese Medicine
- Administration
- Oral
01
Overview
WU-WEI BAO-GAN WAN is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Qingdao Hospital of Traditional Chinese Medicine. It is specifically designed for the treatment of non-alcoholic fatty liver disease (NAFLD), particularly in patients presenting with TCM syndromes of liver stagnation and spleen deficiency, combined with liver and kidney Yin deficiency and blood stasis. The name translates to "Five-Flavor Liver-Protecting Pill," which may refer to the inclusion of *Schisandra chinensis* (Wu Wei Zi) or the five flavors of TCM. The drug has been evaluated in a Phase 1 clinical trial in China to assess its clinical efficacy, safety, and TCM mechanisms compared to polyene phosphatidyl choline.
- Other names
- Wuwei Baogan WanWuwei Baogan Pills
02
Targets
PXR (Pregnane X receptor)
Beyond the preview
Go deeper on WU-WEI BAO-GAN WAN.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WU-WEI BAO-GAN WAN.